Today: The Core Laboratories NV (CLB) PT Raised to $115.00

The Core Laboratories NV (CLB) PT Raised to $115.00

Core Laboratories NV (NYSE:CLB) had its price target upped by analysts at Citigroup Inc. from $110.00 to $115.00 in a research note issued to investors on Tuesday. The brokerage presently has a “neutral” rating on the stock. Citigroup Inc.’s price objective would indicate a potential upside of 2.43% from the company’s previous close.

CLB has been the topic of a number of other research reports. JPMorgan Chase & Co. restated a “buy” rating on shares of Core Laboratories NV in a research report on Thursday, June 30th. DA Davidson assumed coverage on Core Laboratories NV in a research report on Wednesday, October 5th. They issued a “buy” rating and a $136.00 price target on the stock. KLR Group restated a “buy” rating and issued a $180.00 price target (up previously from $166.00) on shares of Core Laboratories NV in a research report on Monday, June 13th. Zacks Investment Research cut Core Laboratories NV from a “buy” rating to a “hold” rating in a research report on Monday, September 26th. Finally, Loop Capital assumed coverage on Core Laboratories NV in a research report on Friday, September 30th. They issued a “hold” rating and a $120.00 price target on the stock. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $121.61.

Core Laboratories NV (NYSE:CLB) opened at 112.27 on Tuesday. The firm’s 50-day moving average is $110.88 and its 200-day moving average is $117.51. The firm has a market capitalization of $4.95 billion, a P/E ratio of 59.56 and a beta of 1.45. Core Laboratories NV has a 52-week low of $84.50 and a 52-week high of $135.49.

Core Laboratories NV (NYSE:CLB) last posted its quarterly earnings data on Wednesday, July 20th. The company reported $0.35 earnings per share for the quarter, hitting the consensus estimate of $0.35. The firm had revenue of $148.10 million for the quarter, compared to analysts’ expectations of $146.37 million. Core Laboratories NV had a return on equity of 344.55% and a net margin of 11.81%. The company’s quarterly revenue was down 27.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.81 EPS. On average, equities analysts expect that Core Laboratories NV will post $1.54 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 22nd. Investors of record on Friday, October 21st will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 1.96%. The ex-dividend date of this dividend is Wednesday, October 19th. Core Laboratories NV’s dividend payout ratio is currently 117.65%.

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in shares of Core Laboratories NV by 4.1% in the first quarter. Geode Capital Management LLC now owns 227,422 shares of the company’s stock valued at $25,549,000 after buying an additional 8,979 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Core Laboratories NV by 20.8% in the first quarter. Goldman Sachs Group Inc. now owns 41,829 shares of the company’s stock valued at $4,702,000 after buying an additional 7,204 shares during the period. State Street Corp raised its position in shares of Core Laboratories NV by 1.6% in the first quarter. State Street Corp now owns 464,720 shares of the company’s stock valued at $52,230,000 after buying an additional 7,339 shares during the period. BB&T Securities LLC raised its position in shares of Core Laboratories NV by 5.5% in the first quarter. BB&T Securities LLC now owns 12,359 shares of the company’s stock valued at $1,389,000 after buying an additional 647 shares during the period. Finally, Credit Agricole S A raised its position in shares of Core Laboratories NV by 29.5% in the first quarter. Credit Agricole S A now owns 16,404 shares of the company’s stock valued at $1,844,000 after buying an additional 3,738 shares during the period.

Core Laboratories NV Company Profile

Related posts

Leave a Comment